Opthea Limited, an Australian headquartered biotech completed its U.S. public offering in 2020 increasing the need to build the U.S. executive team and expand operations.Their novel asset combating retinal swelling, OPT-302, is poised for U.S. clinical success, all they needed was the right team.
With the CEO based in Australia coupled with travel restrictions due to the pandemic meant conducting a completely virtual process. Stevenson's expertise in not only assessing technical and leadership competencies but cultural fit was a key factor to success.
Working closely with CEO, Dr. Megan Baldwin, Stevenson was able to successfully place Opthea’s Chief Medical Officer, Senior Vice President of Global Clinical Operations, Senior Vice President of Regulatory Affairs and Vice President of Manufacturing.
These pivotal appointments will help scale the business and prepare for U.S. approval as well as continue the advancement of the Opthea pipeline.